| treatment |
|
comparator |
Serious adverse event | death (overall survival) | progression or death (progression free survival PFS) | objective response (ORR) | serious adverse events | progression (Time to progression TTP) | hypertension (grade 3) | arterial/venous thromboembolism (grade 3) | cardiomyopathy (grade 3) | gastrointestinal perforation (grade 3) | bleeding (grade 3) | heart failure (grade 3) | permanent discontinuation | treatment-related deaths | clinical benefit |
|
|
| Aflibercept | lung cancer (metastatic), in all type of patients | vs Docetaxel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Ramlau, 2012 | | | platinum-pretreated patients with advanced or metastatic nonsquamous non-small-cell lung cancer |
|
| Pazopanib | lung cancer (metastatic), in all type of patients | vs pemetrexed | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Scagliotti, 2013 | pazopanib in combination with pemetrexed | | first-line treatment of patients with advanced-stage non-small-cell lung cancer |
|
| Sunitinib | lung cancer (metastatic), in all type of patients | vs erlotinib | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Groen, 2013 | sunitinib 37.5 mg/day plus erlotinib 150 mg/day continuously in 4-week cycles | placebo plus erlotinib | second-line treatment of metastatic non-small-cell lung cancer | | Scagliottia, 2012 | | | patients with previously treated advanced non-small-cell lung cancer |
|
| Sunitinib | lung cancer (metastatic), in all type of patients | vs pemetrexed | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Heist CALGB 30704 (Alliance): , 2014 | | | second-line treatment of advanced non-small-cell lung cancer |
|
| Vandetanib | lung cancer (metastatic), in all type of patients | vs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Aisner, 2013 | vandetanib or placebo as maintenance | | patients with advanced non-small-cell lung cancer | | Ahn, 2013 | | | advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy | | de Boer, 2011 | vandetanib 100 mg/d plus pemetrexed 500 mg/m(2) every 21 days | placebo plus pemetrexed | second-line treatment of advanced non-small-cell lung cancer | | Natale, 2009 | | | |
|
| Vandetanib | lung cancer (metastatic), in all type of patients | vs gefitinib | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Natale, 2011 | once-daily vandetanib 300 mg | gefitinib 250 mg | patients with advanced non-small-cell lung cancer |
|
| Vandetanib | lung cancer (metastatic), in all type of patients | vs placebo | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Lee ZEPHYR, 2012 | vandetanib 300 mg/d | placebo | patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor |
|
| Vandetanib | lung cancer (metastatic), in all type of patients | vs placebo plus docetaxel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Heymach, 2007 | vandetanib (100 or 300 mg/d) plus docetaxel (75 mg/m2 intravenous infusion every 21 days) | placebo plus docetaxel | previously treated non small-cell lung cancer |
|
| Docetaxel | lung cancer (metastatic), in all type of patients | vs docetaxel alone | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| REVEL, 2014 | | | patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen |
|
| Sorafenib | advanced breast cancer (metastatic), in all type of patients | vs gemcitabine or capecitabine alone | - | NS | by 36% | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 1.01 [0.71 1.44] | p=1.00 | 0 | -18 | 1 | Schwartzberg, | | progression or death (progression free survival PFS) | 0.64 [0.44 0.93] | p=0.04 | 0 | -18 | 1 | Schwartzberg, | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Schwartzberg, 2013 | sorafenib (400 mg, twice daily) | placebo | patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab |
|
| Sorafenib | advanced breast cancer (metastatic), in all type of patients | vs paclitaxel alone | - | NS | NS | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 1.02 [0.71 1.46] | p=1.00 | 0 | -18 | 1 | Gradishar, | | progression or death (progression free survival PFS) | 0.79 [0.56 1.11] | p=1.00 | 0 | -18 | 1 | Gradishar, | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Gradishar, 2013 | paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off) plus sorafenib (400mg, orally, twice daily) | paclitaxel (90mg/m(2), weekly, intravenously, 3 weeks on/1 week off) | first-line therapy in patients with HER2-negative advanced breast cancer |
|
| Sorafenib | lung cancer (metastatic), in all type of patients | vs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Wakelee, 2012 | | | | | Paz-Ares, 2012 | daily sorafenib (400 mg twice a day) or matching placebo plus gemcitabine (1,250 mg/m(2) per day on days 1 and 8) and cisplatin (75 mg/m(2) on day 1) for up to six 21-day cycles | gemcitabine/cisplatin alone | chemotherapy-naive patients with unresectable stage IIIB to IV nonsquamous non-small-cell lung cancer |
|
| Sorafenib | lung cancer (metastatic), in all type of patients | vs erlotinib | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Spigel, 2011 | | | previously treated advanced non-small-cell lung cancer |
|
| Sorafenib | lung cancer (metastatic), in all type of patients | vs placebo | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Scagliotti, 2010 | up to six 21-day cycles of carboplatin area under the curve 6 and paclitaxel 200 mg/m(2) (CP) on day 1, followed by sorafenib 400 mg twice a day on days 2 to 19 | | chemotherapy-naïve patients with unresectable stage IIIB or IV non-small-cell lung cancer |
|
| Ceritinib | advanced breast cancer (metastatic), in all type of patients | vs fulvestrant | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Hyams, | | | |
|
| Ceritinib | lung cancer (metastatic), in all type of patients | vs carboplatin and paclitaxel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Laurie, 2014 | cediranib 20mg daily to carboplatin/paclitaxel | | patients with advanced non-small cell lung cancer | | Goss, 2010 | | | initial therapy for advanced non-small-cell lung cancer |
|
| Ceritinib | lung cancer (metastatic), in all type of patients | vs gemcitabine and carboplatin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Dy, 2013 | | | first-line therapy in advanced non-small-cell lung cancer |
|
| Bevacizumab | advanced breast cancer (metastatic), in all type of patients | vs capecitabine | - | NS | NS | by 72% | NS | - | by 920% | - | NS | NS | NS | by 268% | NS | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.97 [0.58 1.60] | p=1.00 | 0 | 1077 | 2 | RIBBON-I (Robert) on top capecitabine, AVF2119g (Miller) cape, | | progression or death (progression free survival PFS) | 0.81 [0.50 1.32] | p=1.00 | 0 | 1077 | 2 | RIBBON-I (Robert) on top capecitabine, AVF2119g (Miller) cape, | | objective response (ORR) | 1.72 [1.23 2.42] | p=0.04 | 0 | 948 | 2 | RIBBON-I (Robert) on top capecitabine, AVF2119g (Miller) cape, | | serious adverse events | 1.28 [0.84 1.95] | p=1.00 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | 10.20 [2.44 42.61] | p=0.04 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | 1.88 [0.17 20.86] | p=1.00 | 0 | 444 | 1 | AVF2119g (Miller) cape, | | gastrointestinal perforation (grade 3) | 0.50 [0.01 25.17] | p=1.00 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | bleeding (grade 3) | 0.50 [0.03 8.00] | p=1.00 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | heart failure (grade 3) | 3.68 [1.06 12.83] | p=0.04 | 0 | 1734 | 2 | RIBBON-I (Robert) on top capecitabine, AVF2119g (Miller) cape, | | permanent discontinuation | 1.00 [0.59 1.68] | p=1.00 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | treatment-related deaths | 0.60 [0.18 1.98] | p=1.00 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| RIBBON-I (Robert) on top capecitabine, 2009 | Capecitabine + bevacizumab 15 mg/kg iv every 3 weeks | capecitabine (Cape; 2,000 mg/m(2) for 14 days), | irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer | | AVF2119g (Miller) cape, 2005 | capecitabine + bevacizumab 15 mg/kg iv every 3 weeks | capecitabine (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks | patients with metastatic breast cancer previously treated with an anthracycline and a taxane |
|
| Bevacizumab | advanced breast cancer (metastatic), in all type of patients | vs CT alone | - | NS | NS | NS | - | - | - | - | - | - | - | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.90 [0.46 1.77] | p=1.00 | 0 | 684 | 1 | RIBBON-2 (Brufsky), | | progression or death (progression free survival PFS) | 0.78 [0.43 1.43] | p=1.00 | 0 | 684 | 1 | RIBBON-2 (Brufsky), | | objective response (ORR) | 1.33 [0.91 1.96] | p=1.00 | 0 | 541 | 1 | RIBBON-2 (Brufsky), | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | 4.34 [0.23 81.02] | p=1.00 | 0 | 679 | 1 | RIBBON-2 (Brufsky), | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| RIBBON-2 (Brufsky), 2009 | addition of BV to chemotherapies used as second-line treatment for MBC | chemo+placebo | second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
|
| Bevacizumab | advanced breast cancer (metastatic), in all type of patients | vs docetaxel | - | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 1.01 [0.81 1.25] | p=1.00 | 0 | 471 | 2 | AVADO (Miles) 15mg , AVADO (Miles) 7.5mg, | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| AVADO (Miles) 15mg , 2009 | Docetaxel + bevacizumab 7.5 mg/kg iv every 3 weeks | | first-line treatment of HER2-negative metastatic breast cancer | | AVADO (Miles) 7.5mg, 2010 | bevacizumab 7.5mg/kg every 3 weeks plus docetaxel | placebo plus docetaxel | first-line treatment of HER2-negative metastatic breast cancer |
|
| Bevacizumab | advanced breast cancer (metastatic), in all type of patients | vs methotrexate | - | - | - | NS | - | - | - | NS | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | 3.09 [0.60 15.81] | p=1.00 | 0 | 55 | 1 | Burstein, | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | 1.85 [0.07 47.70] | p=1.00 | 0 | 55 | 1 | Burstein, | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Burstein, 2005 | Methotrexate + cyclophosphamide + bevacizumab 10 mg/kg iv every 2 weeks | | |
|
| Bevacizumab | advanced breast cancer (metastatic), in all type of patients | vs paclitaxel | - | - | NS | NS | NS | - | NS | - | - | - | - | - | NS | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.79 [0.33 1.90] | p=1.00 | 0 | 191 | 1 | Martin bevacizumab, | | objective response (ORR) | 1.24 [0.70 2.20] | p=1.00 | 0 | 191 | 1 | Martin bevacizumab, | | serious adverse events | 0.75 [0.38 1.46] | p=1.00 | 0 | 185 | 1 | Martin bevacizumab, | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | 6.49 [0.78 53.85] | p=1.00 | 0 | 185 | 1 | Martin bevacizumab, | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | 1.70 [0.79 3.68] | p=1.00 | 0 | 185 | 1 | Martin bevacizumab, | | treatment-related deaths | 0.31 [0.03 3.03] | p=1.00 | 0 | 185 | 1 | Martin bevacizumab, | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Martin bevacizumab, 2011 | bevacizumab 10 mg/kg intravenously on days 1 and 15 of each 28-day cycle | control | patients with HER2-negative locally recurrent or metastatic breast cancer |
|
| Bevacizumab | advanced breast cancer (metastatic), in all type of patients | vs taxanes | - | NS | by 37% | by 70% | by 49% | - | by 1498% | NS | - | NS | by 721% | NS | by 47% | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.92 [0.58 1.45] | p=1.00 | 0 | 1344 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | progression or death (progression free survival PFS) | 0.63 [0.41 0.98] | p=0.04 | 0 | 1344 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | objective response (ORR) | 1.70 [1.29 2.22] | p=0.04 | 0 | 994 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | serious adverse events | 1.49 [1.00 2.21] | p=0.04 | 0 | 615 | 1 | RIBBON-I (Robert) on top Tax or anthra, | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | 15.98 [4.48 57.08] | p=0.04 | 0 | 1326 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | arterial/venous thromboembolism (grade 3) | 1.52 [0.49 4.68] | p=1.00 | 0 | 711 | 1 | E2100 (Miller), | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | 3.05 [0.53 17.69] | p=1.00 | 0 | 1326 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | bleeding (grade 3) | 8.21 [1.04 65.09] | p=0.04 | 0 | 1326 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | heart failure (grade 3) | 7.58 [0.94 60.96] | p=1.00 | 0 | 711 | 1 | E2100 (Miller), | | permanent discontinuation | 1.47 [1.08 2.02] | p=0.04 | 0 | 1326 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | treatment-related deaths | 0.78 [0.29 2.07] | p=1.00 | 0 | 1326 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| E2100 (Miller), 2007 | paclitaxel + bevacizumab 10 mg/kg iv every 2 weeks | paclitaxel 90 mg per square meter of body-surface area on days 1, 8, and 15 every 4 weeks | patients with metastatic breast cancer not previously treated | | RIBBON-I (Robert) on top Tax or anthra, 2009 | Taxanes or anthracyclines + bevacizumab 15 mg/kg iv every 3 weeks | taxane (Tax) -based (nab-paclitaxel 260 mg/m(2), docetaxel 75 or 100 mg/m(2)), or anthracycline (Anthra) -based (doxorubicin or epirubicin combinations [doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyclophosphamide, o | irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer |
|
| Bevacizumab | advanced breast cancer (metastatic), in first line therapy | vs capecitabine | - | NS | NS | NS | NS | - | by 920% | - | - | NS | NS | NS | NS | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.85 [0.40 1.82] | p=1.00 | 0 | 615 | 1 | RIBBON-I (Robert) on top capecitabine, | | progression or death (progression free survival PFS) | 0.68 [0.34 1.34] | p=1.00 | 0 | 615 | 1 | RIBBON-I (Robert) on top capecitabine, | | objective response (ORR) | 1.50 [0.98 2.30] | p=1.00 | 0 | 486 | 1 | RIBBON-I (Robert) on top capecitabine, | | serious adverse events | 1.28 [0.84 1.95] | p=1.00 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | 10.20 [2.44 42.61] | p=0.04 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | 0.50 [0.01 25.17] | p=1.00 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | bleeding (grade 3) | 0.50 [0.03 8.00] | p=1.00 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | heart failure (grade 3) | 6.91 [0.90 52.70] | p=1.00 | 0 | 1220 | 1 | RIBBON-I (Robert) on top capecitabine, | | permanent discontinuation | 1.00 [0.59 1.68] | p=1.00 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | treatment-related deaths | 0.60 [0.18 1.98] | p=1.00 | 0 | 605 | 1 | RIBBON-I (Robert) on top capecitabine, | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| RIBBON-I (Robert) on top capecitabine, 2009 | Capecitabine + bevacizumab 15 mg/kg iv every 3 weeks | capecitabine (Cape; 2,000 mg/m(2) for 14 days), | irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer |
|
| Bevacizumab | advanced breast cancer (metastatic), in first line therapy | vs docetaxel | - | NS | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 1.01 [0.81 1.25] | p=1.00 | 0 | 471 | 2 | AVADO (Miles) 15mg , AVADO (Miles) 7.5mg, | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| AVADO (Miles) 15mg , 2009 | Docetaxel + bevacizumab 7.5 mg/kg iv every 3 weeks | | first-line treatment of HER2-negative metastatic breast cancer | | AVADO (Miles) 7.5mg, 2010 | bevacizumab 7.5mg/kg every 3 weeks plus docetaxel | placebo plus docetaxel | first-line treatment of HER2-negative metastatic breast cancer |
|
| Bevacizumab | advanced breast cancer (metastatic), in first line therapy | vs paclitaxel | - | - | NS | NS | NS | - | NS | - | - | - | - | - | NS | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | 0.79 [0.33 1.90] | p=1.00 | 0 | 191 | 1 | Martin bevacizumab, | | objective response (ORR) | 1.24 [0.70 2.20] | p=1.00 | 0 | 191 | 1 | Martin bevacizumab, | | serious adverse events | 0.75 [0.38 1.46] | p=1.00 | 0 | 185 | 1 | Martin bevacizumab, | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | 6.49 [0.78 53.85] | p=1.00 | 0 | 185 | 1 | Martin bevacizumab, | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | 1.70 [0.79 3.68] | p=1.00 | 0 | 185 | 1 | Martin bevacizumab, | | treatment-related deaths | 0.31 [0.03 3.03] | p=1.00 | 0 | 185 | 1 | Martin bevacizumab, | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Martin bevacizumab, 2011 | bevacizumab 10 mg/kg intravenously on days 1 and 15 of each 28-day cycle | control | patients with HER2-negative locally recurrent or metastatic breast cancer |
|
| Bevacizumab | advanced breast cancer (metastatic), in first line therapy | vs taxanes | - | NS | by 37% | by 70% | by 49% | - | by 1498% | NS | - | NS | by 721% | NS | by 47% | NS | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.92 [0.58 1.45] | p=1.00 | 0 | 1344 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | progression or death (progression free survival PFS) | 0.63 [0.41 0.98] | p=0.04 | 0 | 1344 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | objective response (ORR) | 1.70 [1.29 2.22] | p=0.04 | 0 | 994 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | serious adverse events | 1.49 [1.00 2.21] | p=0.04 | 0 | 615 | 1 | RIBBON-I (Robert) on top Tax or anthra, | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | 15.98 [4.48 57.08] | p=0.04 | 0 | 1326 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | arterial/venous thromboembolism (grade 3) | 1.52 [0.49 4.68] | p=1.00 | 0 | 711 | 1 | E2100 (Miller), | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | 3.05 [0.53 17.69] | p=1.00 | 0 | 1326 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | bleeding (grade 3) | 8.21 [1.04 65.09] | p=0.04 | 0 | 1326 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | heart failure (grade 3) | 7.58 [0.94 60.96] | p=1.00 | 0 | 711 | 1 | E2100 (Miller), | | permanent discontinuation | 1.47 [1.08 2.02] | p=0.04 | 0 | 1326 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | treatment-related deaths | 0.78 [0.29 2.07] | p=1.00 | 0 | 1326 | 2 | E2100 (Miller), RIBBON-I (Robert) on top Tax or anthra, | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| E2100 (Miller), 2007 | paclitaxel + bevacizumab 10 mg/kg iv every 2 weeks | paclitaxel 90 mg per square meter of body-surface area on days 1, 8, and 15 every 4 weeks | patients with metastatic breast cancer not previously treated | | RIBBON-I (Robert) on top Tax or anthra, 2009 | Taxanes or anthracyclines + bevacizumab 15 mg/kg iv every 3 weeks | taxane (Tax) -based (nab-paclitaxel 260 mg/m(2), docetaxel 75 or 100 mg/m(2)), or anthracycline (Anthra) -based (doxorubicin or epirubicin combinations [doxorubicin/cyclophosphamide, epirubicin/cyclophosphamide, fluorouracil/epirubicin/cyclophosphamide, o | irst-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer |
|
| Bevacizumab | advanced breast cancer (metastatic), in second line therapy | vs capecitabine | - | NS | NS | by 117% | - | - | - | - | NS | - | - | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 1.07 [0.54 2.11] | p=1.00 | 0 | 462 | 1 | AVF2119g (Miller) cape, | | progression or death (progression free survival PFS) | 0.98 [0.49 1.96] | p=1.00 | 0 | 462 | 1 | AVF2119g (Miller) cape, | | objective response (ORR) | 2.17 [1.25 3.77] | p=0.04 | 0 | 462 | 1 | AVF2119g (Miller) cape, | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | 1.88 [0.17 20.86] | p=1.00 | 0 | 444 | 1 | AVF2119g (Miller) cape, | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | 2.52 [0.52 12.24] | p=1.00 | 0 | 514 | 1 | AVF2119g (Miller) cape, | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| AVF2119g (Miller) cape, 2005 | capecitabine + bevacizumab 15 mg/kg iv every 3 weeks | capecitabine (2,500 mg/m2/d) twice daily on day 1 through 14 every 3 weeks | patients with metastatic breast cancer previously treated with an anthracycline and a taxane |
|
| Bevacizumab | advanced breast cancer (metastatic), in second line therapy | vs CT alone | - | NS | NS | NS | - | - | - | - | - | - | - | NS | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.90 [0.46 1.77] | p=1.00 | 0 | 684 | 1 | RIBBON-2 (Brufsky), | | progression or death (progression free survival PFS) | 0.78 [0.43 1.43] | p=1.00 | 0 | 684 | 1 | RIBBON-2 (Brufsky), | | objective response (ORR) | 1.33 [0.91 1.96] | p=1.00 | 0 | 541 | 1 | RIBBON-2 (Brufsky), | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | 4.34 [0.23 81.02] | p=1.00 | 0 | 679 | 1 | RIBBON-2 (Brufsky), | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| RIBBON-2 (Brufsky), 2009 | addition of BV to chemotherapies used as second-line treatment for MBC | chemo+placebo | second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer |
|
| Bevacizumab | lung cancer (metastatic), in all type of patients | vs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Reck, 2010 | GP+bev | GP | |
|
| Bevacizumab | lung cancer (metastatic), in all type of patients | vs erlotinib alone | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Herbst, 2011 | erl+bev | erl | |
|
| Bevacizumab | lung cancer (metastatic), in all type of patients | vs platinum based CT | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Sandler, 2006 | PCp +bev | PCp | | | Johnson, 2004 | PCp +bev | PCp | | | Nishio, 2009 | PCp +bev | PCp | | | Herbst, 2007 | D/M +bev | D/M | |
|
| Bevacizumab | renal-cell carcinoma (advanced), in all type of patients | vs interferon alpha | - | by 14% | by 32% | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | 0.86 [0.76 0.97] | p=0.04 | 0 | 1381 | 2 | CALGB 90206, AVOREN, | | progression or death (progression free survival PFS) | 0.68 [0.60 0.76] | p=0.04 | 0 | 1381 | 2 | CALGB 90206, AVOREN, | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| CALGB 90206, 2010 | bevacizumab (10 mg/kg intravenously every 2 weeks) plus IFN- (9 million units subcutaneously
three times weekly) | same dose and schedule of IFN- monotherapy | Patients with previously untreated, metastatic clear cell RCC | | AVOREN, 2007 | bevacizumab (10 mg/kg every 2 weeks) plus IFN (9 MIU subcutaneously three times a week) | IFN plus placebo | patients with previously untreated mRCC |
|
| Bevacizumab | renal-cell carcinoma (advanced), in all type of patients | vs placebo | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Yang, 2003 | bevacizumab at doses of 3 and 10 mg per kilogram of body weight, given every two weeks | placebo | patients with metastatic renal-cell carcinoma |
|
| Motesanib | advanced breast cancer (metastatic), in all type of patients | vs paclitaxel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Martin (motesanib), 2011 | motesanib 125 mg orally once per da | placebo | patients with untreated HER2-negative metastatic breast cancer |
|
| Motesanib | advanced breast cancer (metastatic), in first line therapy | vs paclitaxel | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Martin (motesanib), 2011 | motesanib 125 mg orally once per da | placebo | patients with untreated HER2-negative metastatic breast cancer |
|
| Motesanib | lung cancer (metastatic), in all type of patients | vs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Serious adverse event | no data | | death (overall survival) | no data | | progression or death (progression free survival PFS) | no data | | objective response (ORR) | no data | | serious adverse events | no data | | progression (Time to progression TTP) | no data | | hypertension (grade 3) | no data | | arterial/venous thromboembolism (grade 3) | no data | | cardiomyopathy (grade 3) | no data | | gastrointestinal perforation (grade 3) | no data | | bleeding (grade 3) | no data | | heart failure (grade 3) | no data | | permanent discontinuation | no data | | treatment-related deaths | no data | | clinical benefit | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients | Trial | Studied treatment | Control | Patients |
|---|
| Scagliottib MONET1, 2012 | carboplatin (area under the curve, 6 mg/ml · min) and paclitaxel (200 mg/m(2)) intravenously for up to six 3-week cycles plus either motesanib 125 mg | | patients with advanced nonsquamous non-small-cell lung cancer |
|
